ABSTRACT
Atopic
dermatitis
(AD)
is
a
chronic
inflammatory
skin
disease,
characterized
by
an
impaired
epidermal
barrier
and
immunological
alterations.
The
activity
of
the
cytoprotective
NRF2
transcription
factor
reduced
in
epidermis
AD
patients.
To
determine
functional
relevance
this
deficiency,
we
used
mice
lacking
fibroblast
growth
receptors
1
2
keratinocytes
(K5-R1/R2
mice),
which
exhibit
several
AD-like
symptoms.
Proteomics
analysis
their
revealed
Nrf2
activity.
This
was
accompanied
increase
DNA
damage
number
senescent
cells.
Genetic
deletion
these
further
promoted
senescence,
but
time-limited
pharmacological
activation
had
mild
protective
effect.
Surprisingly,
long-term
genetic
K5-R1/R2
caused
strong
hyperkeratosis,
keratinocyte
hyperproliferation,
thickening,
increased
apoptosis
damage,
altered
immune
cell
composition.
These
results
reveal
complex
role
show
necessity
to
optimize
duration
intensity
for
treatment
alterations
patients
with
AD.
Frontiers in Pharmacology,
Journal Year:
2024,
Volume and Issue:
15
Published: Aug. 13, 2024
Background
Tralokinumab,
a
humanized
monoclonal
antibody
targeting
interleukin-13,
has
been
primarily
used
for
the
treatment
of
moderate-to-severe
atopic
dermatitis.
Given
its
extensive
use
in
clinical
practice,
understanding
safety
profile
real-world
setting
is
crucial.
Methods
This
study
utilized
disproportionality
analysis
to
evaluate
tralokinumab
practice
by
analyzing
all
adverse
event
reports
since
2021
FDA
Adverse
Event
Reporting
System
database
that
identified
as
primary
suspected
drug.
odds
ratio,
proportional
reporting
multi-item
gamma
Poisson
shrinker,
and
Bayesian
confidence
propagation
neural
network
were
analyses
events
related
tralokinumab.
Additionally,
Weibull
distribution
was
employed
model
risk
over
time.
Results
reactions
documented
on
drug
label,
such
injection
site
reactions,
conjunctivitis,
upper
respiratory
infections,
displayed
positive
signals.
potential
not
mentioned
label
also
identified,
including
dizziness,
headache,
nausea,
vomiting,
hair
loss,
acne.
The
importance
monitoring,
particularly
first
month
after
initiation,
emphasized.
Conclusion
provided
preliminary
data
application
tralokinumab,
confirming
some
known
revealing
additional
risks.
findings
offer
critical
information
clinicians
prescribing
treat
The Journal of Dermatology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 15, 2024
Tapinarof
is
a
nonsteroidal,
topical,
aryl
hydrocarbon
receptor
agonist
approved
for
the
treatment
of
atopic
dermatitis
(AD)
in
Japanese
patients
aged
≥12
years.
We
evaluated
efficacy
and
safety
tapinarof
pediatric
2
to
11
years
with
AD
phase
2,
multicenter,
randomized,
double-blind,
vehicle-controlled
trial.
Eligible
(N
=
121)
were
randomized
1:1:1
receive
cream
0.5%,
1%,
or
vehicle
once
daily
8
weeks.
At
week
8,
least-squares
mean
percent
change
from
baseline
Eczema
Area
Severity
Index
(EASI)
score
(the
primary
endpoint)
was
-81.29%
0.5%
group,
-77.62%
1%
-
18.56%
group.
Reductions
EASI
at
significantly
greater
groups
than
group
(p
<
0.0001
both
comparisons).
The
proportion
≥75%
improvement
77.5%
70.7%
15.0%
who
achieved
an
Investigator's
Global
Assessment
0
(clear)
1
(almost
clear)
≥2-grade
32.5%
43.9%
17.5%
No
treatment-related
serious
adverse
events
(AEs)
reported;
all
AEs
mild
moderate.
Common
tapinarof-treated
included
gastroenteritis,
application
site
irritation,
nasopharyngitis.
incidence
trial
discontinuations
due
low
(one
patient
each
strength).
In
summary,
strengths
demonstrated
well
tolerated
AD.
Pediatric Allergy and Immunology,
Journal Year:
2025,
Volume and Issue:
36(2)
Published: Feb. 1, 2025
Abstract
The
skin
is
a
large
and
sophisticated
organ
populated
by
innate
adaptive
immune
effector
cells.
These
cells
provide
critical
first
line
of
defense
against
pathogens,
but
genetic
environmental
factors
can
lead
to
inappropriate
signaling
that
may
manifest
as
hypersensitivity.
most
common
cutaneous
allergic
disorders
in
children
include
atopic
dermatitis,
urticaria/angioedema,
contact
dermatitis.
In
this
review,
we
will
briefly
review
these
conditions,
with
focus
on
recent
developments
our
understanding
the
diagnosis
management
disorders.
